Condition: Hematological Malignancy · Solid Tumor · Sponsor: Onward Therapeutics
This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of hematological malignancies and solid tumors. In the dose of escalation part it is to characterize the overall safety and tolerability profile and determine the recommended dose(s) of OT-A201 as monotherapy, and in various combination regimens. Preliminary information about anti-cancer activity will be further explored in the expansion part of the study.
This description comes directly from the study's public registry record.
Bruno Piccolella · +33 6 12 97 73 68 · bruno.piccolella@onward-therapeutics.com
Erica Wang · +886 921 865 855 · erica.wang@onward-therapeutics.com
Always discuss trial participation with your own doctor first.
| ICM - Montpellier | Montpellier, France | Recruiting |
| Saint-Eloi Hospital - Montpellier (CHU) | Montpellier, France | Recruiting |
| Saint-Joseph Hospital - Paris | Paris, France | Recruiting |
| Centre Eugène Marquis | Rennes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05828459